Journal: Journal of clinical pharmacy and therapeutics
Article Title: Effect of memantine combination therapy on symptoms in patients with moderate-to-severe depressive disorder: randomized, double-blind, placebo-controlled study.
PMID/MRN: 27809351
Publication Date: 2016-Nov-03
Abstract:
Current treatments for depressive disorders are far from optimum. This study was planned to evaluate possible antidepressant effects and safety of memantine, a selective N-methyl-d-aspartate receptor antagonist, in humans.
Sixty-six outpatients with the diagnosis of moderate-to-severe major depressive disorder, based on DSM-V diagnostic criteria, were recruited to participate in a parallel, randomized, controlled trial. Sixty-two participants completed 6Êweeks of treatment with either memantine (20Êmg/day) plus sertraline (200Êmg/day) or placebo plus sertraline (200Êmg/day). Patients were evaluated using the Hamilton Depression Rating Scale (HDRS) at baseline and at weeks 2, 4 and 6. Comparison of treatment efficacy in improving depressive symptoms between the two groups was the principal outcome measure.
A repeated-measures analysis demonstrated significant timeÊ*Êtreatment interaction on HDRS score [F (2á09, 125á67)Ê=Ê5á09, PÊ=Ê0á007]. Significantly greater improvement was seen at all three follow-up sessions as well as significantly greater response rates at weeks 4 and 6 (PÊ=Ê0á018 and PÊ<Ê0á001, respectively) in the memantine group. Significantly more early improvers and more rapid response to treatment were observed in the memantine group (PÊ=Ê0á001 and PÊ<Ê0á001, respectively). A significant reduction was observed in HDRS score from baseline to the study endpoint in both memantine (PÊ<Ê0á001, Cohen's dÊ=Ê12á71) and placebo groups (PÊ<Ê0á001, Cohen's dÊ=Ê5á13). No serious adverse event occurred. No significantly greater remission rate was seen in the adjunctive memantine therapy.
A 6-week course of treatment with memantine as adjunct to sertraline showed a favourable safety and efficacy profile in patients with major depressive disorder. Nonetheless, larger controlled studies of longer duration are necessary to assess long-term safety, efficacy and optimal dosing.
© 2016 John Wiley & Sons Ltd.